Search - tctmd.com

Displaying 1 - 20 of 561

Sort: Relevancy | Date

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Daily News

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

Caitlin E. Cox

March 25, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

Caitlin E. Cox

March 19, 2026

News Daily News

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Michael O'Riordan

March 13, 2026

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

Caitlin E. Cox

February 02, 2026

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Advertisement

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

What’s Going to Be Hot at ACC 2026

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Side Effects of Statins Might Be Overstated: CTT Collaboration

TCTMD’s Top 10 Most Popular Stories for January 2026

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content